Loading…
Employees: 166
Size Shanghai MicuRx Pharmaceutical (688373.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $495M, the 3889th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.03 on 6 Nov 2026.
Performance Over six months the shares fell 16.4%, against -18.1% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 23.1% over the last twelve months (peer median -0.4%); the operating margin is -60.9% (peer median 3.6%).
Valuation It trades at 19.6× enterprise value to sales against a peer median of 3.9× (2nd most expensive of 19).
Capital Return on invested capital runs 54.7 points below its cost of capital (8.0% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥168M | CN¥142M | CN¥130M | CN¥90.8M | CN¥48.2M |
| Revenue growth | — | +9% | +43% | +88% | — |
| Gross profit | CN¥145M | CN¥102M | CN¥90.1M | CN¥56.2M | CN¥21.9M |
| EBITDA | n/a | -CN¥229M | -CN¥422M | -CN¥422M | -CN¥240M |
| Net income | -CN¥95.9M | -CN¥242M | -CN¥441M | -CN¥421M | -CN¥220M |
| Free cash flow | -CN¥91.8M | -CN¥213M | -CN¥428M | -CN¥300M | -CN¥237M |
| Capital expenditure | CN¥8,975 | CN¥549,087 | CN¥914,765 | CN¥7.66M | CN¥12.2M |
| Total debt | CN¥341M | CN¥380M | CN¥302M | CN¥221M | CN¥230M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688373.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | -8.9% | 11th highest of 21 |
| 6-month return | -16.4% | -18.1% | 10th highest of 20 |
| Distance from 52-week high | -35.5% | -42.2% | 7th highest of 21 |
| Revenue growth (TTM) | +23.1% | -0.4% | 4th highest of 19 |
| Operating margin | -60.9% | 3.6% | 4th lowest of 19 |
| EV / Sales | 19.6× | 3.9× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -54.7 pp | -3.3 pp | 2nd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |